Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
139.56(c) 138.5(c) 136.46(c) 136.71(c) 138.86(c) Last
3 780 329 4 254 177 5 151 061 4 175 750 4 306 128 Volume
-0.09% -0.76% -1.47% +0.18% +1.57% Change
More quotes
Financials ($)
Sales 2017 13 248 M
EBIT 2017 7 532 M
Net income 2017 4 348 M
Debt 2017 3 768 M
Yield 2017 -
Sales 2018 15 455 M
EBIT 2018 8 866 M
Net income 2018 5 702 M
Finance 2018 1 297 M
Yield 2018 -
P/E ratio 2017 24,62
P/E ratio 2018 19,00
EV / Sales2017 8,48x
EV / Sales2018 6,95x
Capitalization 109 B
More Financials
Company
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in... 
Sector
Pharmaceuticals
Calendar
10/26 | 01:30pmEarnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
10:06a CELGENE CORPORATION : - Results from Phase 2 Studies of Oral Ozanimod in Crohn's..
10/17 IBD Announces First Annual Biotech Innovator Awards
10/17 CELGENE : More positive ozanimod data bolsters the drug`s profile
10/16 CELGENE CORPORATION : Today's Research Reports on Stocks to Watch: Celgene Corpo..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and U..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease..
10/13 CELGENE : Sutro Marks Two Drug Development Milestones
10/12 CELGENE : Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology A..
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/07 BRISTOL MYERS SQUIBB : Industry Leaders Gather at Medidata NEXT Global 2017 to D..
More news
Sector news : Pharmaceuticals - NEC
08:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
08:24a RECKITT BENCKISER : to form two business units for better focus
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on CELGENE CORPORATION 
CELGENE CORPORATION - 08/10
The resistance should give in
BUY
CELGENE CORPORATION - 04/28
Hesitation should subside in favor of volatility
BUY
More Strategies
Latest Tweets
11:06aBar Harbor Trust Services Has $240,000 Holdings in Celgene Corporation $CELG .. 
10:49aProficio Capital Partners LLC Has $289,000 Stake in Celgene Corporation $CELG.. 
06:31a$CELG - Zacks: Analysts Expect Celgene Corporation #CELG to Post $1.88 EPS  
01:22aSee why @Celgene made this year's list of IBD's first Biotech Innovator Award..
2
10/17On The Fly: Top five analyst initiations $GRPN $HPE $CELG $HIVE $SFM
1
More tweets
Qtime:487
News from SeekingAlpha
10/17 VALUE SYSTEM : Amgen Looks Undervalued
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/17 Premarket analyst action - healthcare
10/16 President Trump at it again with comments on "out of control" drug prices
10/14 Stocks to watch next week
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 155 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION17.89%108 637
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423